Restenosis limits the long-term beneficial effects of percutaneous transluminal coronary angioplasty and related procedures (1) . The importance of diabetes as a consistent clinical predictor for restenosis after angioplasty has been demonstrated in several studies. The initial report from the National Heart, Lung, and Blood lnstitute Angioplasty Registry t2) indicated that the angiographic restenosis rate in diabetic patients was 47% compared with 32% in nondiabetic patients. Subsequent studies have reported restenosis rates of 49% to 71% among diabetic patients (3) (4) (5) (6) (7) (8) (9) . New angioplasty devices failed to make any major impact on the rcstenosis rate among diabetic patients. Diabetes is associated with a twofold increase in recurrent clinical events after directional coronary atherectomy (10). Likewise, diabetic patients have higher restenosis rates after stent placement (I 1) and after cxcimer laser angioplasty (12).
Restenosis is viewed as an intraluminal growth process after an arterial injury (see below), and risk factors for restenosis are likely to be risk factors for this growth process. In contrast to diabetes, other traditional risk factors for atherosclerosis, such as male gender, hypertension, hypercholesterolemia and continued smoking after angioplasty, have been reported as risk factors only inconsistently (1,3,7.8) . In attempting to predict restenosis from clinical variables. Weintraub et al. (3) concluded that "the problem is that each of the clinical variables is a correlate without a clear relation to the underlying pathophriological process." The intent of this review is to examine some of the putative mechanisms involved in the resterross process in light of pathophysiologic events currently known to occur in the diabetic state. From (J Am cdl clydid 1!%27528-35)
Pathophysiologic Mechanisms of Restenosis in Relation to Diabetes
The complex pathophysiologic events leading to restenosis after balloon injury involve endothelial denudation; platelet deposition with mural thrombosis; vascular smooth muscle ceil proliferation and migration; and extracellular matrix synthesis (13-17). Intimal smooth muscle cell hyperplasia is the predominant histologic finding in restenotic lesions (18). A fundamental element in the development of intimal hyperplasia is the transformation of smooth muscle cells from a contractile to a proliferative. secretory phenotype. The restenosis process is initiated when balloon inflation causes endothelial denudation and deep vessel injury. Tine exposure of subendothelial elements initiates platelet adhesion and activation. Activated platelets at the site of injury secrete growth factors that release smooth muscle cells from growth inhibition and induce their proliferation and subsequent migration from the media to the intima (15,17). Smooth muscle cell proliferation continues beyond the phase of platelet deposition (14). Activated smooth muscle cells themselves secrete growth factors that can act on surrounding cells and help to sustain proliferation and migration (19). The proliferative response becomes quiescent several months after intervention.
A second fundamental element of restenosis is the production and secretion of extracellular matrix by smooth muscle cells that have migrated into the injured intimal zone (17). The neointima is generally hypocellular, composed predominantly of extracellular matrix material thdt forms the bulk of neointimal growth (13,16).
Although vessel recoil may also contribu:e to loss of lumen, the markedly increased restenosis rate seen in diabetic patients after stent placement (11) underscores the role oi enhanced smooth muscle cell proliferation as the major mechanism for restenosis in these patients, because coronary artery stenting provides a rigid endovascular lattice that prevents both elastic recoil and vascular spasm at the treated site (11). 'R3F-a = nan&mkng growth f-&or-w TCF+ = km&ming growth f&%x-beta; TxA, = thrombOZdlKA,
In the diabetic state, several mechanisms combine to promote the various processes that constitute the biology of the restenosis process (Fig. 1) . In the following section, these mechanisms are discussed.
Endothelial Dysfunction
The removal of the endothelial lining by balloon injury and the endothelial dysfunction that persists during endothelial regeneration both amtribute to the rcstenosis process by promoting thrombosis, vasoamstriction and smooth muscle cell growth. The amount of endothelial denudation appears to correlate with the degree of later neointimal thickness (20). Furthermore, endothelial layer regeneration after vascular injury is critical in determining the eventual lesion formation (1521). Indeed, intimal hyperplasia is greater in areas where end&&l regeneration occurred last (14). The integrity and function of the endothelial cell layer are profoundly altered in diabetic animals and humans ( Table   1 ). The best-characterized endothelial abnormality is impaired endotheliumdependent relaxation (Z-24). impaired endotheliumdependent relaxation can be induced by short exposure (several hours) to high glucose concentration (2225) and occurs in ditferent vascular beds including the coronary arteries (26).
Diabetes can impair endotbelium-dependent relaxation by at least hvo mechanisms: 1) Advanced glycosylation end products (see later) have been shown to rapidly inactivate endotheliumderived relaxing h tar in vitro through a direct chemical reaction (273). 2) Increased generation of oxygen free radicak, which occurs in diabetes (2229) also inactivates endotheliumderived relaxing factor before it can exert its action on smooth muscle celk (2530). Vasospasm at the dilated coronary artery segment occurs commonly and may contribute to the early reduction in gain and promote clot formation (31). However, the loss of endotheliumderived relaxing factor has a profound effect on the arterial wall beyond the tendency to vasospasm because it inhibits both platelet aggregation and smooth muscle cell proliferation (32-34).
P~~~tacyclin is another endothelial vasodilator that ako inhibits platelet aggregation and adhesion to the endothelium (34). Diabetes-induced alterations in prostaglandin metabolism result in a reversible decrease in prostacyclin production by endothelial celk (3536).
Endothelin-I is a potent natural vasoconshictor synthesized and secreted from endothelial cells; it is also a mitogen for smooth muscle cells (32). Plasma endothelin-1 concentrations are signihcantly increased in diabetic patients (37). Physiologic concentrations of insulin enhance the transcription rate and secretion of endothelin-1 mRNA in endothelial cells (38,39). Hence, the hyperinsulinemic state that characterizes type II diabetes may result in a continual stimulus for endothelin-1 production and secretion.
In addition to the impaired function of endothelial celk, diabetes affects their migration and proliferation. Human vascular endothelial cell replication in culture is inhibited in the presence of high glucose concentrations (40.41). In spontaneously diabetic rats, the regeneration of the endothelium after catheter deendothelialization is slower than control rats, resulting in prolonged interaction of platelets with the denuded vessel and, subsequently, in greater neointimal proliferation (42).
The impaired ability of endothelial cells to regenerate after balloon injury along with the functional alterations in local production of vasodilators, antiaggregants and antiproliferative molecules that occur in diabetes are likely to have a considerable effect on the restenosis process by decreasing reendothelialization. increasing the propensity to thrombosis and reducing the capacity of endothelial cells to produce the appropriate growth inhibitors for smooth muscle cells.
Platelet Aggregation and Thrombus Formation
The earliest finding after balloon dilation is platelet deposition along the denuded surface. often with subsequent thrombus formation. The importance of thrombus formation in the restenosis process is emphasized by the observation that severe thrombocytopenia induced by antiplatelet antibodies inhibits neointimal accumulation after vascular injury (43) . Similarly, antibodies directed against the platelet IIb/IIIa receptor integrin have been shown to significantly decrease the clinical restenosk rate (44).
Platelets that adhere and aggregate at sites of endothelial disruption release several prothrombotic, rasoconstrictive and growth-promoting mediators ( Table 2 ) that stimulate neointimal growth (154546) and have sustained biilogical effects on myointimal hyperplasia long alter platelet deposition and thrombosis have resolved (31).
In diabetic patients, elevated fractions of activated platelets circulate in the absence of clinically detectable vascular lesions (47) . In addition, platelets from diabetic subjects exhibit an enhanced adhesiveness, and hyperaggregabihty in response to various agonists, including epinephrine, co&en, arach&& acid and thrombin (48) (49) (50) . Platelet extracts from diabetic patients have been shown to have signScantly greater growthpromoting potential for smooth muscle celk in ctdture than rhose from control subjects. However, after intensive insuhn therapy, the platelet growth activity of these patients sign& candy declined and became similar to control levek (51) .
Thromboxane A, a potent platelet activator and vasoconstrictor, is synthesized in platelets during platelet activation. Increased thromboxane A2 concentrations at sites of endothelial injury facilitate platelet aggregation and contribute to the neointimal proliferative response (52) . Enhanced activity of the platelet arachidonic acid pathway with increased thromboxane A2 synthesis occurs in diabetic subjects (53) . There is a significant correlation between thromboxane AZ produaion and fasting plasma glucose or hemoglobin A,,-, and normal thromboxane AZ production can be restored by strict glycemic control (4954).
The ahnormal platelet function in diabetes is reflected in platelet interaction with deendothelialized vessek after balloon injury. Platelet accumulation on the injured aorta of diabetic rats is prolonged compared with control rats (42). resulting in a thicker intima with a greater number of layers of smooth muscle cells m diabetic rats (42).
Other abnormalities in the coagulation system in diabetic patients that enhance platelet aggregation and thrombus formation includ elevated fibrinogen levek (55, 56) , increased Factor VII levels in response to hyperglycemia (5657) and a decrease in the biological activity of antithrombin III as a result of nonenzymatic glycosylation of the lysine residue that binds it to its natural cofactor, heparin (56) . In addition, a characteristic feature of insulin resistance and hyperinsulinemIa is reduced plasma fibtinolytic activity caused by increased plasminogen activator inhibitor I activity (5859). In vitro studies (60) have shown that proinsulin, a precursor of insulin, augments plasminogen activator inhibitor 1 gene expression in hepatocytes, resulting in an increased synthesis by the liver, which is the primary source >I this molecule in plasma.
III hummar),, alterations m hemostatic mechanisms in the diabetic state can lead to further recruitment of platelets and mural thrombus formation through hypersensitivity of platelets to agonists at sites of vessel injury, decreased effectiveness of the inhibited thrombolytic system and elevated clotting factor levels. reming factw, ET-1 = e&tbelia-1; HS = hepatan sutt%te; IGF-1 = india-like growth f-&or-l; PDGF = platektdcrived grwth facts, WC = smooth mude cell; TGF-beta = vansforming growth factorbeta.
Dysregulatim of Growth Factor Expression
The metabolic alterations associated with diabetes darn promote restenosis through unique alterations in local growth factor production and action, which in turn may induce proliferation of smooth muscle cells and extracellular matrix synthesis (Table 2) . Alterations in growth factor expression have been implicated in the pathogenesis of proliferative diabetic retinopathy as well as in the mesangial cell proliferation and excessive matrix deposition that characterize diabetic nephrop athy (61,62). Because many of these mitogenic mediators are overexpressed by vascular smooth muscle cells and endothelial cells in diabetic patients, it is reasonable to assume that they contriiute to restenosis.
Platelet-Derived Growth Factor and
Insulin-Like Growth Factor-i
Platelet-derived growth factor is a "competence factor" for smoothmusdecellsinthatitenablestheceUtomclve~mthe quiescent (i.e., contractUe) phenotype into the active phase of replication (63). Progx&n into actual replication requires a second class of growth fact-termed "ptogre&on facto-" which trigger "competence" factor-primed cells to prohferate. One of the progression factors for plateletderived growth factor-mediated cell grmvth is insulin-like growth factor-l (64j. Higher concentrations of insulin-like growth factor-l have been demonstrated in smooth muscle cells of the synthetic phenotype from restenotic human coronary atherectomy plaques compared with smooth muscle cells of the contractile phemv (65). Smooth muscle cells from diabetic rats grow faster than normal smcoth musde cells in response to platelet-derived growth factor (66) and after balloon catheter injury (67). These cells egress more platelet-derived growth factor-betareceptor mRNA, which is typically expressed on the contractile phenotype of smooth muscle cells (66,67). llms, vascular smooth musc!e cells may be more sensitive to the growth stimulatory action of platelet-derived growth factor in the presence of diabetes.
Alterations in insulin-like growth factor-l regulation that lead to increased expression and elevated tissue level of this growth factor have been implicated in the pathogenesis of renal hypertrophy in diabetic nephro@ry (6168). Similarly, insulin-like growth factor-l may be imolved in the pathogen-esis of accelerated diabetic retinopathy (69) as patients with diabetic retinopathy have elevated insulin-like growth factor-l levels in the vitreous humor (70). The role of insulin-like growth factor-l in the development of macrovascular lesions is less clear.
Insulin as a Growth Factor for Vascular
Smooth Muscle Cells Physiologic concentrations of insulin are known to stimulate proliferation of cultured smooth muscle cells and fibroblasts (71,72). Although insulin itself is a poor mitogen (73). it can potentiate the expression of the more potent mitogen insulin-like growth factor-l (74,75). Thus, in the presence of insulin resistance, where the metabolic action of insulin is ineffective, the proliferative response to hyperinsulinemia may still occur.
Transforming Growth Factor-Beta
Transforming growth factor-beta is the most important growth factor regulating the extracellular matrix production that characterizes intimal hyperplasia in its advanced stages (13,76,77). In the rat carotid artery injury model, administration of neutralizing antitransforming growth factor-beta antibodies reduces matrix accumulation in intimal lesions (78). Transforming growth factor-beta expression has been investigated in diabetes in relation to diabetic nephropathy because one of its dominant features is the expansion of extracellular matrix in the mesangial areas. In animal models of diabetes, the expression of transforming growth factor-beta in the kidney increases within a few uays of the appearance of hyperglycemia (6279) in association with active production of matrix components in the glomeruli (62). The increase in transforming growth factor-beta mRNA and protein in diabetic rats can be attenuated with insulin treatment (62). Recently, increased transforming growth factor-beta mRNA and protein were demonstrated in kidneys of patients with advanced diabetic nephropathy (62).
The expansion of the extracellular matrix in diabetic nephropathy bears many similarities to the extracellular matrix accumulation that results from arterial injury. In this context, it should be emphasized that mesangial cells act as specialized contractile smooth muscle cells that produce extracellular matrix components (80) . Termination of extracellular matrix deposition is essential to avoid excessive neointimal growth after balloon catheter injury. Thus, failure to regulate or terminate transforming growth factor-beta expression in the presence of diabetes may potentially lea,l to excessive matrix deposition with greater encroachment on the arterial lumen.
Other Growth Factors
Hyperglycemia affects the expression of several other growth factors such as basic fibroblast growth factor and transforming growth factor-alpha (81) . Smooth muscle cells exposed to high glucose concentrations increase their basic fib&last growth factor mRNA levels (81) . Basic fib&last growth factor is a potent mitogen for smooth muscle celk and may be involved in restenosis, because rats treated with blocking antibodies to basic tibrobkst growth factor have decreased smooth muscle cell proliferation after balloon catheter injury (82) . Transforming growth factor-alpha k known to be expressed in smooth muscle and endothelial cells (45.81) . llms, when overexpressed in the presence of hyperglycemia, it may promote restenosis.
Increased myointimal proliferation and matrix deposition in diabetic patients may be a consequence of altered production of local or circulating growth factors and/or modulations in the response to these factors. The cellular events that lead to altered regulation of growth factor expression in diabetes are largety unkmnvn. Regulation of growth factor expression by glucose seems to occur at the tramcriptional level and may be mediated by one of its intracellular metabolites (81) . Regardless of the mechanism involved, the presence of diabetes can selectively alter gene expression in smooth muscle cells, leading to dysregulation of growth factors that are known mediators of the restenosis process.
Abnormal Elxtracellular Matrix Composition-Role of Heparan Sulfate
The extracellular matrix regulates cell migration proliferation and matrix production by means of cytoskeletal signals and by posttranslational control of growth factors (83). An important factor in the release from growth inhiiition following balloon injury is the loss of inhibitory control of the surrounding proteoglycan matrix. Matrix-associated heparan sulfate is a potent inhibitor of smooth muscle cell proliferation and plays an important role in the regulation of smooth muscle cell growth in injured arteries (13,17&t). After balloon injury, endoth&d hudatioir, disruption of the prOieO&Giil matrix of the medial layers and activated platelet release of endoglycosidases that cleave heparan sulfate from the surface of smooth muscle cells all lead to the loss of the inhtbitory effect of heparan sulfate. In addition, the removal of heparan sulfate renders cells receptive to growth factors and contributes to their phrnotypic modulation (13,14,17).
Hy-rerglycemia induces an increase in selected matrix gene transcription that persists for weeks after restoration of normoglycemia in vivo (85). This results in an incraed synthesis of extracellular matrix components such as collagen type IV, libronectin and laminin. Abnormalities in the synthesis and metabolism of heparan sulfate have been repeatedly reported in association with both experimental and human diabetes (79, 86, 87) . The density of heparan sulfate has been shown to be significantly reduced in the glomerular basement membrane of patients with diabetic nephropathy (79, 86, 87) . Hyperglycemia causes a decrease in the de novo synthesis of heparan sulfate (88) probably because of decreased activity of the enzyme Mdeacetylase, which plays a key role in its biosynthesis (89). Interestit@, the administration of protamine as part of commmly used insulin preparations exacerbates smooth musde cd proliferative lesions after balloon injury in rats and interferes with the grrxtth inhiitory effects of heparin in cuhltreandhvivo(90).
In summuy, diminution of matrix-bound heparan sulfate can mnlt in loss of tonic growth inhiition and facilitate smooth muscle cell proliferation. Hyperglycemia-induced augmentation in matrix component production may increase neo iotimal VohJme (F-Ii. 1).
Role of Advmced Glycosylatim End Products in Restenosis
Advaaad glycqlation end products are a heterogeneous clas of mmenaymatically gtycosylated adducts of proteins or Iipidsthata#xtlmuIateinvasallartissueswithagingandatan accderated rate in diabetes The degree of nonenzymatic glyaqlation is determined mainly by tbe glucose concentration and time of exposure (91-94). Advaxed Hation end prodU&areabmldantinmosttissu~aod!hlidsand,through the induct& of qtokines and growth-promoting mediators, may partic&te in tissue remodeling (91-94). Advanced glycosylation is implicated in the initiation and acceleration of multiple organ damage in diabetic patients, including macrowscular disease, nephropathy, and neuropathy (91~%), and mayalsopromotetberestenosisprocess.
Advamd gjpsylation end pmducts interact with vessel wall ceUular components through a specitic receptor system present on various cell types, including monocyt~ endothelial cells and smooth muscle cells (94,%,97). Monocyte receptormediated interaction with advanced glyco@ation end products tesultsintheprodWionofmediatorssuchastumornecrosis factor-alpha, plateletderived growth factor and insulin-like growth factor-l (98-100).
Momxytes and lymphocjtes are known io migrate into the tbrombtts that forms in the balloon injury site. This cellular infiltrate may be an abundant source of growth factors and chemonztant substances, facilitating and sustaining further cellular recruitment and smooth muscle cell growth (15-17). The presence of advanced glycosylation end products in the exposed vessel wall wutld be expected to promote the migration of intlammatoty cells into the lesion with tbe subsequent release of growth-promoting cytokines. Furthermore, spccitic binding of glycosylated proteins by cultured rat smooth muscle cells is associated with increased cellular proliferation (9394) that is likely to be cytokine or growth factor mediated.
Finally, advanced glycosylation end products influence the expression of selected extracelluhu matrix genes (e.g.. collagen type IV, laminin) as well a5 transforming grcwth factor-beta (101). Advanced glycosylation also alters the functional prop erties of several important matrix constituents Glyccsylation of matrix components such as collagen IV, laminin and vitronectinwiUdecreasebindingofanionic heparan sulfate, leading to greater turnover of heparan sulfate (92,102). Glycosylation of the extracellular matrix also alters the normal interactions of transmembranc integrin receptors with their specific matrix ligands. For example, moditicdtion of the cell-binding domains of type Iv collagen causes decreased ertdotbelial cell adhesion (92JE).
!3tuwmy. Advamxdglya@ationendproductscanmedi-ate intlammatory cell recruitment and activation, stimulation of smooth muscle cell proliferation and abnormal matrix production, all of which can promote the restenosis process conclusions Diabetes iniluertces various cellular events involved in the vessel mspomie to injury (Fig. 1) . lbe same mechanisms can potentially play a role in the intimal proliferation that causes luminal loss in tire hrst years after bypass surgery with venous cotlduit (103).
An important question is whether the restenosis rate can be reduced in diabetic patients. Pharmaco@ic manipulations for the prevention of restenosis are based on insights into the pathophy&logic me&a&m of restenosis and include growth factor inhibitors (e.g, Wapidil) (17) new antithrombotic agents (44), antiinflammatory agents and gene therapy (14.17). However, it may be posr&le to use simpler measures in diabetic patients. Many of the potential mechanisms promoting restenosis in diabetic patients are related to elevated glucose or insulin levels, or both Moreover, the majority of these abnormalities are reverst&le on improved glycemic control. Therefore, we anticipate that rigorous glycemic control may reduce the restenosis rate in diabetic patients. However, some of the alteration induced by the metabolic abnormalities of the diabetic state may not be readily reversible. For example, hyperglycemia-induced gene transcription may persist for weeks after restoration of normog&emia in vivo (85). This phenomenon has been termed hyperglycemic memory and may reflect irreversible imraceUular and extracellular effects of hyperglycemia (&5,102). In addition, normoglycemia is frequently achieved at the price nf peripheral hyperinsulinemia. Clinical trials are needed to evaluate the impact of tight glycemic control on restenosis rates among diabetic patients. 
